Business Wire

OpenOcean–IQM-Lakestar State of Quantum 2022: 63% of Business Leaders Believe Commercialised Quantum Computing to Hit the Market in Five Years

16.11.2022 13:32:00 EET | Business Wire | Press release

Share

Today, OpenOcean, a leading European venture capital firm, IQM Quantum Computers, a European leader in quantum computers, and Lakestar, the leading European technology investor, have released the OpenOcean–IQM-Lakestar State of Quantum 2022 Report, in association with The Quantum Insider (TQI). The report shows that 91% of business leaders are investing or planning to invest in quantum computing, a field in which private investment has grown 500% from a total of $0.4 billion in 2017 to $2.2 billion in 2021.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221116005481/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

OpenOcean–IQM-Lakestar State of Quantum 2022 Report (Graphic: Business Wire)

This whitepaper is based on a new online, cross industry survey about quantum readiness along with investment data from TQI and other data sources, collating responses from business leaders across the world to understand their preparation and readiness for commercialised quantum computing.

The findings of this report indicate the means through which investors and decision-makers can bridge the gap between the speed and direction of quantum development and what customers are ready and planning for – tapping into the value created by commercial use cases.

Key findings:

  • 70% of business leaders are using and developing real-life use cases for quantum computing.
  • 61% of business leaders are planning to invest $1 million or more in quantum computing over the next 3 years.
  • 63% of business leaders believe that commercialised quantum computing will hit the market in 5 years.
  • 76% of business leaders agreed that there is a skills crisis in quantum computing: slowing innovation and needing to be addressed as a priority.
  • 61% of business leaders said the hardware costs of running quantum computing are currently not sustainable.
  • Only 10% of firms are cautious that quantum computing will ever be functional for everyday usage.

Preparing for the quantum era

Understanding where the industry currently stands is a critical step for those who wish to take advantage of everything quantum computing has to offer. Investor and customer appetite for real-world use cases and generic, error-correcting quantum machines is growing fast.

Despite challenges arising around the shortage of quantum talent and hardware costs, a significant percentage (33%) of firms see at least an application-specific future for the technology. These businesses understand that quantum computing will bring immense challenges and change over the next few years, identifying the three sectors prime for transformation as cybersecurity; finance; and healthcare, including drug discovery and pharmaceutical research.

Ekaterina Almasque, General Partner at OpenOcean, said: “Our research confirms that we are on a one-way journey to enter the quantum era. The findings are a clear sign that the broader market is starting to buy into the potential of quantum computing, recognising its emerging commercial potential and backing it with significant investment. There is a unique opportunity now for first-movers and businesses to carve out an impactful strategy to operate in the new quantum realm. It was encouraging to see software development as a priority for investment - this is where we also see the dire need for advancements.

“Our mission as an early stage investor in frontier technologies, is to support emerging European leaders in the quantum computing space. These technologies are already hitting the market, and will expand and advance in the decades ahead. The industry is searching for sound investment strategies and concrete examples of added value; this is why we need to be looking for practical solutions. For businesses to make their mark in a competitive landscape, they will need full stack quantum solutions – built and designed for the problems which need most solving.”

Dr. Jan Goetz, CEO and Co-founder of IQM Quantum Computers, said: “I am pleased to see from this report that business leaders in Europe, APAC, and North America are already using quantum computing and are planning significant R&D investments in the near future. With quantum technologies, we can expect several use cases like improvements in drug discovery, encryption and data protection, prediction of financial systems and solutions to other problems. We’ll see significant transformation in industries by bringing together hardware and software, developing application-specific capabilities, and addressing most pressing problems.

“At IQM, we have developed an on-premises strategy to partner with HPC centers and businesses, and this report marks the continuation of our commitment to work with businesses and create a fastlane to quantum advantage.”

Stephen Nundy, Partner & CTO at Lakestar, said: “We fundamentally believe that in order for quantum to reach its full potential in both the short and long term, we must encourage investment and experimentation in quantum software to allow early adoption that feels naturally accretive to existing platforms and technology developed already.

“Customers do not, and should not, need to be quantum-savvy to be able to develop and deploy hybrid quantum applications which solve real-world problems, create business advantages, and harness the best native quantum hardware available. There is certainly much to be excited about in this new computer paradigm - the opportunity for quantum software and hardware companies to work together to build viable platforms for commercial and societal use is already upon us.”

Read the OpenOcean-IQM-Lakestar State of Quantum 2022 Whitepaper here: State of Quantum 2022 Report

About OpenOcean

OpenOcean is an early-stage venture capital firm investing across Europe with offices in London and Helsinki. With an entrepreneurial background from building several category-defining software businesses, we engage with founders to build and scale global companies delivering data solutions for the new economy. OpenOcean typically leads or co-leads Series A funding rounds.

About IQM Quantum Computers

IQM is the pan-European leader in building quantum computers. IQM provides on-premises quantum computers for supercomputing centres and research labs and offers full access to its hardware. For industrial customers, IQM delivers a quantum advantage through a unique application-specific, co-design approach. IQM is building Finland’s first commercial 54-qubit quantum computer with VTT, and an IQM-led consortium (Q-Exa) is also building a quantum computer in Germany. This computer will be integrated into an HPC supercomputer to create a quantum accelerator for future scientific research. IQM has over 200 employees with offices in Paris, Madrid, Munich, and Espoo.

About Lakestar

Lakestar’s mission is to find, fund and grow disruptive businesses - enabled by technology - that are founded by exceptional entrepreneurs in Europe and beyond. Founded by Klaus Hommels, the team’s early investments include Skype, Spotify, Facebook and Airbnb. Since raising its first fund in 2012, Lakestar manages an aggregated volume of over €1.2bn across three early stage funds and a growth fund.

The team actively advises and supports portfolio companies in marketing, recruitment, technology, product development and regulatory insight, accompanying founders from seed to early stage to growth stage or exit. Lakestar currently has the privilege of holding investments in Revolut, Blockchain.com, Opendoor, Oscar, GetYourGuide, sennder, Eigen, Public.com, SoFi, Solarisbank, Uncapped, Yapily, Terra Quantum, accuRx, Rhino, ZEBEDEE and Hometogo to name a few. Lakestar has presence in Berlin, Zurich and London.

###

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

IQM Media Contact
Raghunath Koduvayur, Head of Marketing and Communications
Email: Raghunath@meetiqm.com
Mobile: +358 50 4876509
www.meetiqm.com

OpenOcean Media Contact
Alex Izza, Account Director
Email: alex@resonancecrowd.com
Mobile: +44 (0) 759 189 9654
www.openocean.vc

Lakestar Media Contact
Tom Climie
Email: tom.climie@kekstcnc.com
Tel.: +44 7760 160 248

Marisa Wagner
Email: marisa.wagner@kekstcnc.com
Tel: +49 152 543 727 77
www.lakestar.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release

Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o

Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release

Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a

DAYBU ® (trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 13:49:00 EEST | Press release

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating condition," said Catherine Owen Adams, Acadia’s Chief Executive Officer. “Our commitment is to make a meaningful difference in the lives of patients, caregivers, and the wider Rett com

HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 12:18:00 EEST | Press release

HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi

Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 11:28:00 EEST | Press release

Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye